HERC1 expression has prognostic potential in human AML. (A) HERC1 expression was analyzed in a total of 34 different tumor types using the TCGA database. Statistical analysis was performed using a 1-way ANOVA followed by Holm-Šídák multiple comparisons test. ∗P ≤ .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. (B) HERC1 expression was analyzed in a panel of 1296 different cell lines. Statistical analysis was performed as described in panel A. (C) Kaplan-Meier analysis of the BEAT-AML data set based on HERC1 expression (n = 132). (D) Kaplan-Meier analysis of the BEAT-AML data set based on HERC1 expression (n = 132). (E-F) Similar to panels C-D respectively, except that DCK was analyzed instead. Statistical analysis was performed using the Mantel-Cox test. ∗P ≤ .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast adenocarcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OPSCC, oropharyngeal squamous cell carcinoma; OV, ovarian cancer; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.